Leaderboards/Ocular Oncology and Treatments

Ocular Oncology and Treatments

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Sapna P. Patel
The University of Texas MD Anderson Cancer Center
90
2
J. M. Górriz
Universidad de Granada
85
3
Ramin Ajami
Informa Healthcare
79
4
Mandeep S. Sagoo
Moorfields Eye Hospital NHS Foundation Trust
76
5
Eszter Szalai
University of Pecs
71
6
M. Ali Aboudzadeh
University of the Basque Country
70
7
Motoko Yamaguchi
Mie University
69
8
Yasmine Shaaban
Mansoura University
68
9
Luz Elena Concha del Río
Asociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes
55
10
Lin Wang
Stomatology Hospital
53

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Mehrab Pourmadadi
Shahid Beheshti University
99
2
Syed A. Hussain
University of Sheffield
68
3
Jules Fricker
Hôpital de la Croix-Rousse
59
4
Hui Qi
Sun Yat-sen University
59
5
Sally Moore
University Hospitals Bristol NHS Foundation Trust
59
6
Vânia Hungria
São Germano Oncologia
52
7
Bertil Damato
Moorfields Eye Hospital NHS Foundation Trust
52
8
Benjamin Abaidoo
University of Ghana
52
9
Masood Naseripour
Iran University of Medical Sciences
52
10
Keri McLean
University of Liverpool
52

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Caroline Robert
Université Paris-Sud
99
2
Jamie R. Rich
Zymeworks (Canada)
97
3
Jacoline E. C. Bromberg
Erasmus MC Cancer Institute
83
4
Udai S. Kammula
National Cancer Institute
78
5
Bertil Damato
Royal Liverpool University Hospital
78
6
Andrzej Jakubowiak
University of Chicago Medical Center
75
7
Carola Berking
LMU Klinikum
74
8
J. William Harbour
Sylvester Comprehensive Cancer Center
72
9
Barbara J. Bain
St Mary's Hospital
72
10
Jerry A. Shields
Thomas Jefferson University
58

All-Time Leaders Papers

1
Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine|2015
5.8k cit.
2
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
New England Journal of Medicine|2018
1.8k cit.
3
The Rb/E2F pathway: expanding roles and emerging paradigms
Genes & Development|2000
1.2k cit.
4
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
JAMA|2016
1.1k cit.
5
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Journal of Clinical Oncology|2017
480 cit.
6
Single-cell analysis reveals new evolutionary complexity in uveal melanoma
Nature Communications|2020
476 cit.
7
An Accurate, Clinically Feasible Multi-Gene Expression Assay for Predicting Metastasis in Uveal Melanoma
Journal of Molecular Diagnostics|2010
351 cit.
8
BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma
BMC Cancer|2013
154 cit.
9
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
The Oncologist|2009
123 cit.
10
Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i>
Clinical Cancer Research|2011
120 cit.

Reagents for Ocular Oncology and Treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Agilent/Dako

Melan A, Melanoma Antigen Recognized by T-Cells

Cited in 6 papers
#M7196
View Evidence →Cell Signaling Technology

PFKP (D2E5) Rabbit Monoclonal Antibody

#12746$161
View Evidence →Agilent/Dako

Melanasome

#M0634
View Evidence →

🌟 All-Time

Most validated

Santa Cruz Biotechnology

BAP1 (C-4)

Cited in 15 papers
#sc-28383
View Evidence →Cell Signaling Technology

Actinomycin D

Cited in 7 papers
#15021$137
View Evidence →Cell Signaling Technology

PathScan® Phospho-S6 Ribosomal Protein (Ser235/236) Sandwich ELISA Kit

Cited in 7 papers
#7205$661
View Evidence →